HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027

Participants enrolled in less than five months from first participant dosing, representing the fastest site activation and enrolment in the HEALEY ALS Platform Trial so far Anticipated topline efficacy and safety results for NUZ-001 accelerated to Q2 CY2027 Completion of recruitment materially de-risks execution of Neurizon's lead late-stage clinical program Reflects strong recruitment and effective execution across the HEALEY ALS Platform Trial network Participants now progressing through the planned 36-week randomised treatment period Neurizon® Therapeutics Limited (ASX: NUZ; OTCQB: NUZTF ) ("Neurizon" or "the Company"), a late-stage clinical biotechnology company dedicated to advancing innovative treatments for neurodegenerative diseases, is pleased to advise that enrolment has been completed in Regimen I of the Phase 2/3 HEALEY ALS Platform Trial evaluating the Company's lead investigational therapy NUZ-001 for the treatment of amyotrophic lateral sclerosis (ALS).

Neurizon advises that the final participant has completed their baseline visit and commenced treatment, completing enrolment into Regimen I. Reflecting the rapid pace of recruitment, the Company now expects to report topline efficacy and safety results in late Q2 CY2027, earlier than previously anticipated. Completion of enrolment, together with the earlier anticipated timing of the topline results readout, further demonstrates the continued advancement of the late-stage clinical development program for NUZ-001 for the treatment of ALS.

Regimen I completed enrolment in less than five months from first participant dosing, becoming the fastest regimen to activate sites and complete enrolment in the HEALEY ALS Platform Trial, even after the planned sample size expansion from 160 to 240 participants in response to strong recruitment momentum. This achievement reflects the strength of recruitment across the HEALEY ALS Platform Trial network, one of the world's leading ALS clinical trial initiatives, the operational efficiencies introduced under the trial's next generation master protocol, and the commitment of investigators, research coordinators and clinical site teams across the United States.

Neurizon sincerely acknowledges every person living with ALS and their families who has chosen to participate in this research, recognising that their commitment is fundamental to advancing clinical research and the development of potential new treatment options for the ALS community. Participants will now continue through the 36-week Randomised Controlled Trial phase before entering the 36-week Active Treatment Extension phase, with the Company's focus centred on continued execution ahead of the anticipated topline readout in late Q2 CY2027.

Interim Executive Chairman, Mr Sergio Duchini said: "Completion of enrolment represents a major milestone in the clinical development of NUZ-001. Importantly, the rapid completion of recruitment has enabled the anticipated timing of topline efficacy and safety results to be accelerated into late Q2 CY2027, bringing forward an important value inflection point for Neurizon and our shareholders. On behalf of the Company, I would like to sincerely thank every person living with ALS and their families who chose to participate in this trial. Their willingness to contribute to research despite the immense challenges of this disease is inspiring and is fundamental to advancing the development of new treatment options for people living with ALS. I would also like to acknowledge the outstanding work of the HEALEY ALS Platform Trial team, investigators, research coordinators and clinical site teams whose expertise, collaboration and commitment have made this achievement possible. With recruitment now complete, our focus turns to delivering the study with the same operational discipline that has characterised the program to date. We look forward to advancing NUZ-001 through clinical develo..."